Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY S SHEA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1962440271
CMS profile
846017
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,000.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Grant $3,000.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Genentech, Inc. $3,000.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY S SHEA

NPI 1962440271 · CMS profile ID 846017

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962440271?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY S SHEA, NPI 1962440271, CMS profile ID 846017. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962440271?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BARRY S SHEA, NPI 1962440271, CMS profile ID 846017. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962440271?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BARRY S SHEA, NPI 1962440271, CMS profile ID 846017, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1962440271?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $3,000.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech, Inc. $3,000.0001/11/2021 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835891667 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $106.49 1
PY2020 $1,600.00 1
PY2021 $3,000.00 1
PY2023 $2,516.64 3
PY2024 $8,890.56 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $517,136.76 122
PY2024 Principal investigator $255,055.64 14
PY2023 Recipient $835.42 1
PY2023 Principal investigator $159,468.38 6
PY2020 Principal investigator $16,207.00 1
PY2019 Recipient $140.92 1
PY2019 Principal investigator $51,828.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

122 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,040.00 12/15/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220795049
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,997.10 12/15/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220795051
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657222
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657224
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 12/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795031
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 12/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795033
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 12/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220795035
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,277.00 11/25/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220795047
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657218
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657220
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 11/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795027
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 11/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795029
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,967.80 10/28/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795021
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 10/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657226
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 10/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657228
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657214
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657216
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 10/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795023
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 10/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795025
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,295.00 10/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220795045
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27,117.12 09/25/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220795043
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 09/24/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657212
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,154.80 09/24/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220795013
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,154.80 09/23/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220795011
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,240.00 09/04/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220795007
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,240.00 09/04/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220795009
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,292.20 09/02/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795019
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657208
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657210
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 09/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795015
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 09/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220795017
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657204
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657206
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 08/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794973
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 08/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794975
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657054
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657056
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 07/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794969
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 07/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794971
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 06/24/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657044
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657046
Principal investigator 1 Boehringer Ingelheim International GmbH $6.30 06/24/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657048
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 06/24/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657050
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 06/24/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657052
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657030
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657032
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,840.50 06/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794957
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 06/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794965
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 06/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794967
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6.59 06/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220795003
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 05/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657038
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 05/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657040
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 05/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657042
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,064.20 05/07/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794955
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28.00 05/02/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794963
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657026
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657028
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657136
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657160
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657200
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657202
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 05/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794959
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 05/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794961
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 05/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220795001
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 04/23/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657034
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 04/23/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657036
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,313.30 04/10/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1236000718
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,698.60 04/09/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220795037
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657132
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657158
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657194
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657196
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 04/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794951
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 04/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794953
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 04/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794999
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 03/25/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657024
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657130
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 03/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657134
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657142
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657190
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657192
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 03/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657198
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 03/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794993
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 03/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794995
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 03/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794997
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 02/25/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657016
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 02/25/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657018
Principal investigator 1 Boehringer Ingelheim International GmbH $3.36 02/25/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657020
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 02/25/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220657022
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,816.80 02/18/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794949
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,050.00 02/07/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794945
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,062.00 02/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220795005
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657120
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657122
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657124
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657126
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657128
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657140
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 02/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794987
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 02/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794989
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 02/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794991
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 01/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657144
Principal investigator 1 Boehringer Ingelheim International GmbH $14.02 01/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657146
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657148
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657150
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657152
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657154
Principal investigator 1 Boehringer Ingelheim International GmbH $1.60 01/27/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657156
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,480.00 01/22/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220795041
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,666.30 01/21/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220795039
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,134.81 01/21/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1236000720
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $289,631.00 01/13/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1236000722
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,225.30 01/06/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794947
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657114
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657116
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657118
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220657138
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657186
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220657188
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 01/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794981
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 01/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794983
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 01/01/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794985